Curated Health Wellness News

NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.

Experience Quality Urgent Care at Our Walk-In Clinic in Aurora

December 14, 2024Destiny Urgent Cares of Colorado offers exceptional urgent care services at their walk-in clinic in Aurora, providing accessible and affordable healthcare solutions. Patients can receive timely treatment for a variety of medical issues in a welcoming environment, establishing the clinic as a reliable option for families in need of immediate care.


Revolutionizing Gut Microbiota Research with Innovative Technologies

December 13, 2024Creative Biolabs revolutionizes gut microbiota research with new LBP development technologies, including DGGE, FISH, real-time PCR, 16S rRNA sequencing, and culturomics. The company's work has significant implications for personalized medications and the future of healthcare.


Cogent Infotech Launches CWS Health to Drive Innovation in Healthcare Industry

December 12, 2024Cogent Infotech launches CWS Health, offering customized Health IT and innovative Workforce solutions to empower organizations and address healthcare challenges. The new entity aims to drive innovation within the healthcare industry, ultimately leading to improved patient care and operational excellence.


Okogen Inc. Secures $3.3 Million in Financing for Innovative Eyecare Solutions

December 11, 2024Okogen Inc. secures $3.3 million in financing to advance innovative eyecare solutions for acute infectious conjunctivitis. The funding supports the development of an AI-driven image evaluation platform and triple-combination eyedrop treatment, addressing significant gaps in managing the highly contagious condition.


Clene (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Application for CNM-Au8 ALS Treatment

December 10, 2024Clene (NASDAQ: CLNN) receives FDA guidance on leveraging data from its ongoing expanded access programs (“EAPs”) to support an accelerated approval application for CNM-Au8, its treatment for ALS. The FDA recommended using neurofilament light chain (“NfL”) biomarker analyses to substantiate the drug’s efficacy. Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 RESTORE-ALS trial. Clinical findings presented at an FDA meeting highlighted CNM-Au8’s significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy.


RedHill Biopharma Wins $8 Million Court Judgment Against Kukbo Co. Ltd.

December 9, 2024RedHill Biopharma secures $8 million court judgment in its favor, signaling a major legal and financial win. The ruling eliminates potential stock overhang and boosts investor confidence, showcasing the company's commitment to contractual agreements and progress in developing opaganib for infectious diseases.